Results 1 to 10 of about 2,604,331 (176)

An Overview of Target Membrane Proteins for Near-Infrared Photoimmunotherapy [PDF]

open access: yesPharmaceuticals
Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer treatment that utilizes antibody–photoabsorber (IRDye700DX [IR700]) conjugates and NIR light.
Motofumi Suzuki, Hirofumi Hanaoka
doaj   +5 more sources

Near-Infrared Photoimmunotherapy in Brain Tumors—An Unexplored Frontier [PDF]

open access: yesPharmaceuticals
Near-infrared photoimmunotherapy (NIR-PIT) is a promising cancer treatment that uses near-infrared light to activate a conjugate of a monoclonal antibody (mAb) and a photoactivatable silica phthalocyanine dye (IRDye700DX: IR700).
Haruka Yamaguchi   +13 more
doaj   +5 more sources

Near infrared photoimmunotherapy of cancer; possible clinical applications

open access: yesNanophotonics, 2021
Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that uses an antibody-photo-absorber conjugate (APC) composed of a targeting monoclonal antibody conjugated with a photoactivatable phthalocyanine-derivative dye, IRDye700DX (IR700 ...
Wakiyama Hiroaki   +4 more
doaj   +4 more sources

Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective

open access: yesBiomedicines, 2022
The conventional treatment of thoracic tumors includes surgery, anticancer drugs, radiation, and cancer immunotherapy. Light therapy for thoracic tumors has long been used as an alternative; conventional light therapy also called photodynamic therapy ...
Kohei Matsuoka   +3 more
doaj   +5 more sources

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy [PDF]

open access: yesCancer Immunology, Immunotherapy
Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective cancer therapy based on a targeted monoclonal antibody conjugated to phthalocyanine-based photoabsorber, IRDye700DX (IR700). Following injection, near-infrared light activates the conjugate
Motofumi Suzuki   +8 more
doaj   +4 more sources

Enhanced nanodrug delivery in tumors after near-infrared photoimmunotherapy [PDF]

open access: yesNanophotonics, 2019
To date, the delivery of nanosized therapeutic agents to cancers largely relies on the enhanced permeability and retention (EPR) effects that are caused by the leaky nature of cancer vasculature. Whereas leaky vessels are often found in mouse xenografts,
Inagaki Fuyuki F.   +3 more
doaj   +3 more sources

Adding Intratumoral Antibody-Photoabsorber Conjugate Improves Efficacy of Near-Infrared Photoimmunotherapy (NIR-PIT). [PDF]

open access: yesCancer Sci
Intravenous (IV) or intratumoral (IT) cetuximab distribution in A431 tumor (essence of Figure 2). ABSTRACT Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer treatment that specifically kills target cells while sparing normal tissue. This treatment induces cancer cell death by activating a photoreactive dye with near‐infrared light in ...
Kano M   +9 more
europepmc   +2 more sources

Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective [PDF]

open access: yesImmunoTargets and Therapy
Ryu Okada,1– 3,* Mizuki Yamada,1,3,4,* Mitsuo Sato,1,4 Kazuhide Sato1,3,51Graduate School of Medicine, Nagoya University, Nagoya, Japan; 2Research Unit for Life Sciences with Light Modulation, B3 Unit, Institute for Advanced Research ...
Okada R, Yamada M, Sato M, Sato K
doaj   +2 more sources

Synthetic zipper mediated pre-targeting system for near-infrared photoimmunotherapy [PDF]

open access: yesiScience
Summary: Several strategies have gained attraction in cancer diagnosis and therapy, particularly to overcome the limitations associated with direct targeting approaches in radioimmunotherapy and photoimmunotherapy.
T.M. Mohiuddin   +7 more
doaj   +2 more sources

Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin

open access: yesCells, 2020
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable.
Yuko Nishinaga   +17 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy